To challenge the potential of EV markers CD14, GPC4, ANXA11, and CD44v6 in detecting PDAC patients, we analyzed their levels in a larger cohort of patients with PDAC and underlying pancreatic diseases: chronic pancreatitis and intraductal papillary mucinous neoplasm (IPMN) (Figure 8C). Here, ANXA11 is linked to pancreas disorder.